Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI)
Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI)
复制标题
DOI：
10.1002/cncr.23227
复制
发表时间：
2008-02-15
期刊：
影响因子：
6.2
通讯作者：
Lyden, Maureen
中科院分区：
文献类型：
--
作者：
Vicini, Frank;Beitsch, Peter D.;Lyden, Maureen
背景资料。这份报告介绍了美国乳房外科医生协会MammoSite(马萨诸塞州，贝德福德，Cytyc)乳房近距离放射治疗注册试验中登记的患者3年来的治疗效果、美容效果和毒性的数据。方法：共有1440名早期乳腺癌患者(1449例)接受了MammoSite设备的治疗，以提供加速部分乳房照射(APBI)(34Gy3.4Gy次)。其中浸润性乳腺癌(IBC)1255例(87%)，导管原位癌(DCIS)194例(13%)。中位随访时间为30.1个月。结果：23例(1.6%)患者在2年的精算中发生了同侧乳腺肿瘤复发(IBTR)。发生率为1.04%(IBC为1.11%，DCIS为0.59%)。没有变量与IBTR相关。6例(0.4%)患者发生腋窝衰竭。术后12个月(980例)、24个月(752例)、36个月(403例)、48个月(67例)的乳房美容优良率分别为95%、94%、93%和93%。乳房浆液性肿块的发生率为23.9%(开放式植入物占30%，封闭式植入物占19%)。10.6%的患者出现有症状的血清肿块，1.5%的患者出现脂肪坏死。对前400例连续登记的病例(352例合并IBC，48例DCIS)进行了亚集分析。中位随访期37.5个月，3年精确率为1.79%。结论：MammoSite装置APBI治疗3年后的疗效、美容和毒性均良好，与报道的其他形式APBI相似的随访结果相似。
BACKGROUND. This report presents 3 years of data on treatment efficacy, cosmetic results, and toxicities for patients enrolled on the American Society of Breast Surgeons MammoSite (Cytyc, Bedford, Mass) Breast Brachytherapy Registry Trial.METHODS. A total of 1440 patients (1449 cases) with early stage breast cancer who were undergoing breast-conserving therapy were treated with the MammoSite device to deliver accelerated partial breast irradiation (APBI) (34 Gy in 3.4 Gy fractions). Of these, 1255 (87%) cases had invasive breast cancer (IBC; median size = 10 mm), and 194 (13%) cases had ductal carcinoma in situ (DCIS; median size = 8 mm). Median follow-up was 30.1 months.RESULTS. Twenty-three (1.6%) cases developed an ipsilateral breast tumor recurrence (IBTR) for a 2-year actuarial. rate of 1.04% (1.11% for IBC and 0.59% for DCIS). No variables were associated with IBTR. Six (0.4%) patients developed an axillary failure. The percentages of breasts with good to excellent cosmetic results at 12 (n = 980), 24 (n = 752), 36 (n = 403), and 48 months (n = 67 cases) were 95%, 94%, 93%, and 93%, respectively. Breast seromas were reported in 23.9% of cases (30% in open-cavity implants and 19% in closed-cavity implants). Symptomatic seromas occurred in 10.6% of cases, and 1.5% of cases developed fat necrosis. A subset analysis of the first 400 consecutive cases enrolled was performed (352 with IBC, 48 DCIS). With a median follow-up of 37.5 months, the 3-year actuarial rate of IBTR was 1.79%.CONCLUSIONS. Treatment efficacy, cosmesis, and toxicity 3 years after treatment with APBI using the MammoSite device are good and similar to those reported with other forms of APBI with similar follow-up.